Clinical Trials · NCT03239119
The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Enrollment
- 456
- Start date
- Nov 2017
- Locations
- See registry
- Primary endpoint
- Change in HbA1c from Baseline to Week 30